Identity
- Security key
- 14398
- Ticker
- DRUG
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2021-03-08
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- DRUG
Detail
Enriched 2026-08-14 20:47
- Market cap
- $778,783,281.57
- Shares outstanding (class)
- 9,732,161
- Shares outstanding (weighted)
- 9,812,061
- SIC
- —
- Employees
- 25
- Location
- —
- Homepage
- https://www.brightmindsbio.com
- Description
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Market cap and share counts drift.